Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
21.9 EUR | +4.29% | +9.50% | -25.00% |
Dec. 18 | Marinomed Biotech Considers Partnerships, Potential Transfer of Carragelose Portfolio | MT |
Dec. 14 | Marinomed Biotech Signs Deal With DKSH to Commercialize Carragelose in Four Countries | MT |
Sales 2023 * | 13.5M 14.56M | Sales 2024 * | 18.5M 19.95M | Capitalization | 33.62M 36.27M |
---|---|---|---|---|---|
Net income 2023 * | -5M -5.39M | Net income 2024 * | - 0 | EV / Sales 2023 * | 3.68 x |
Net Debt 2023 * | 16.05M 17.31M | Net Debt 2024 * | 17.11M 18.46M | EV / Sales 2024 * | 2.74 x |
P/E ratio 2023 * |
-6.54
x | P/E ratio 2024 * |
-36.8
x | Employees | 43 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 64.98% |
Latest transcript on Marinomed Biotech AG
1 day | +4.29% | ||
1 week | +9.50% | ||
Current month | -4.78% | ||
1 month | -3.52% | ||
3 months | -29.81% | ||
6 months | -45.66% | ||
Current year | -25.00% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 55 | 05-12-31 | |
Founder | 56 | 05-12-31 | |
Pascal Schmidt
DFI | Director of Finance/CFO | 52 | 18-07-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 58 | 07-12-31 | |
Brigitte Ederer
BRD | Director/Board Member | 68 | 18-11-20 |
Director/Board Member | - | 22-06-14 |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 21.9 | +4.29% | 7,678 |
24-03-27 | 21 | +0.96% | 2,141 |
24-03-26 | 20.8 | +5.58% | 597 |
24-03-25 | 19.7 | -0.76% | 88 |
24-03-22 | 19.85 | -0.75% | 336 |
Delayed Quote Wiener Boerse, March 28, 2024 at 12:35 pm EDT
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-25.00% | 36.32M | |
+0.44% | 90.78B | |
+9.61% | 43.96B | |
-16.67% | 31.34B | |
+44.99% | 23.45B | |
-9.42% | 16.48B | |
-25.92% | 15.03B | |
-9.27% | 12.79B | |
-7.57% | 12.19B | |
+0.07% | 8.5B |